Effectiveness of Cortiment® in Patients With Ulcerative Colitis
NCT02586259 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 378
Last updated 2019-11-20
Summary
The purpose of this study is to evaluate Cortiment® with regard to its use by clinicians in routine clinical practice and its effectiveness and tolerability in a real-life setting.
Conditions
Interventions
- DRUG
-
budesonide MMX®
Sponsors & Collaborators
-
Ferring Pharmaceuticals
lead INDUSTRY
Principal Investigators
-
Global Clinical Compliance · Ferring Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-12-31
- Primary Completion
- 2018-04-05
- Completion
- 2018-04-05
Countries
- Canada
- Germany
- Ireland
- Italy
- Netherlands
- Poland
- Sweden
- United Kingdom
Study Locations
More Related Trials
-
Determination of the Optimal Treatment Target in Ulcerative Colitis
NCT04259138 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study)
NCT04340895 ·Status: COMPLETED ·Phase: NA
-
Relationship Between Baseline Burden of Disease and TDM in Ulcerative Colitis
NCT03808506 ·Status: WITHDRAWN
-
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
NCT00801723 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
NCT02065622 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis
NCT00385736 ·Status: COMPLETED ·Phase: PHASE3
-
Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis
NCT05341401 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Mercaptopurine Therapy in Ulcerative Colitis
NCT02910245 ·Status: UNKNOWN ·Phase: PHASE3
-
Open-Label Adalimumab for Ulcerative Colitis Patients
NCT00421642 ·Status: COMPLETED ·Phase: PHASE1
-
Chronotherapy in Inflammatory Bowel Disease
NCT04304950 ·Status: COMPLETED ·Phase: PHASE4
-
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
NCT03341962 ·Status: TERMINATED ·Phase: PHASE2
-
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets
NCT01100112 ·Status: COMPLETED ·Phase: PHASE3
-
Diet Intervention Treatment for Active Ulcerative Colitis
NCT04121806 ·Status: RECRUITING ·Phase: NA
-
The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis
NCT00805285 ·Status: TERMINATED ·Phase: PHASE2
-
Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
NCT02506179 ·Status: COMPLETED
-
Mesalazine (PENTASA®) in Ulcerative Colitis
NCT01517607 ·Status: COMPLETED
-
Clinical Outcome of Treatment of Ulcerative Colitis in Adult
NCT06143163 ·Status: NOT_YET_RECRUITING
-
Feasibility of a Multimodal Intervention Program to Optimize Treatment Outcomes in Ulcerative Colitis
NCT05743153 ·Status: UNKNOWN ·Phase: NA
-
Budesonide for Induction of Remission in Incomplete Microscopic Colitis
NCT02142634 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
NCT02738125 ·Status: COMPLETED
-
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
NCT03801928 ·Status: COMPLETED
-
The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis
NCT05180279 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of BBT-401-1S in Ulcerative Colitis
NCT03800420 ·Status: TERMINATED ·Phase: PHASE2
-
Oncostatin M in Ulcerative Colitis Patients
NCT05974332 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336 ·Status: RECRUITING ·Phase: PHASE2